Roundtable
Roundtable
Advertisement
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
View More
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel discusses triplet combinations in development for RCC.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel discusses the disappointing results of the COSMIC-313 trial.
Monty Pal, MDRoundtable | March 15, 2023
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
Monty Pal, MDRoundtable | March 15, 2023
The panel shares how they treat frontline papillary kidney cancer.
Brian Rini, MD, FASCORoundtable | March 14, 2023
The panel discusses treatment-related toxicities and when to consider stopping treatment.
Monty Pal, MDRoundtable | March 14, 2023
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
Brian Rini, MD, FASCORenal Cell Carcinoma | March 10, 2023
The panel compares three treatment regimens.
Monty Pal, MDRoundtable | March 10, 2023
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
Brian Rini, MD, FASCORoundtable | March 10, 2023
The panel discusses the CheckMate 8Y8 clinical trial.
Monty Pal, MDRoundtable | March 10, 2023
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
Monty Pal, MDRoundtable | March 9, 2023
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
Monty Pal, MDRoundtable | March 9, 2023
The panel compares three TKI/IO treatment combinations.
Monty Pal, MDRoundtable | March 9, 2023
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
Brian Rini, MD, FASCORoundtable | March 7, 2023
The panel discusses which patients in their practices would be candidates for ipilimumab/nivolumab combination.
Brian Rini, MD, FASCORoundtable | March 6, 2023
The panel discusses monotherapy treatment for RCC.
Brian Rini, MD, FASCORoundtable | March 2, 2023
The panel discusses how they each approach debulking nephrectomy in their RCC patients.
Monty Pal, MDRoundtable | March 1, 2023
A panel discusses 4 frontline RCC treatment options.
Brian Rini, MD, FASCORoundtable | February 28, 2023
Dr. Rini is joined by a panel of RCC experts to discuss patient characteristics that impact treatment selection.
GU Oncology Now EditorsRoundtable | April 6, 2022
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Advertisement
Advertisement
Advertisement